1 day Ago By ABMN Staff
Russell Investments Group Ltd. grew its position in Cellebrite DI Ltd. ( NASDAQ:CLBT – Free Report ) by 191.
6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 150,416 shares of the company’s stock after purchasing an additional 98,833 shares during the period. Russell Investments Group Ltd.
owned approximately 0.07% of Cellebrite DI worth $3,314,000 at the end of the most recent quarter. Other institutional investors have also recently modified their holdings of the company.
True Wind Capital Management L.P. increased its holdings in Cellebrite DI by 18.
2% in the 4th quarter. True Wind Capital Management L.P.
now owns 13,861,007 shares of the company’s stock worth $305,358,000 after buying an additional 2,130,386 shares during the period. Principal Financial Group Inc. purchased a new stake in shares of Cellebrite DI in the 3rd quarter valued at $23,402,000.
Lord Abbett & CO. LLC acquired a new stake in shares of Cellebrite DI in the third quarter worth $11,523,000. Pertento Partners LLP increased its stake in shares of Cellebrite DI by 26.
7% in the fourth quarter. Pertento Partners LLP now owns 2,975,374 shares of the company’s stock worth $65,547,000 after acquiring an additional 626,373 shares during the period. Finally, Raymond James Financial Inc.
purchased a new position in shares of Cellebrite DI during the fourth quarter worth $9,995,000. 45.88% of the stock is currently owned by hedge funds and other institutional investors.
Cellebrite DI Stock Down 1.6 % NASDAQ:CLBT opened at $19.03 on Thursday.
The stock has a market capitalization of $4.56 billion, a PE ratio of -13.69, a price-to-earnings-growth ratio of 4.
27 and a beta of 1.44. Cellebrite DI Ltd.
has a 52 week low of $10.25 and a 52 week high of $26.30.
The stock’s 50-day moving average price is $19.23 and its 200-day moving average price is $20.02.
Analyst Ratings Changes Several equities research analysts have weighed in on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 price target on shares of Cellebrite DI in a research report on Wednesday, April 2nd.
JPMorgan Chase & Co. upped their target price on Cellebrite DI from $24.00 to $28.
00 and gave the stock an “overweight” rating in a research note on Tuesday, February 11th. Finally, Lake Street Capital raised their target price on Cellebrite DI from $17.00 to $26.
00 and gave the stock a “buy” rating in a report on Friday, February 14th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $23.43.
View Our Latest Stock Report on CLBT Cellebrite DI Company Profile ( Free Report ) Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Featured Stories Want to see what other hedge funds are holding CLBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellebrite DI Ltd. ( NASDAQ:CLBT – Free Report ).
Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter ..
